Page 1 Procollagen Cproteinase enhancer1 PCPE1 potential biomarker therapeutic target ﬁbrosis Priscillia Lagoutte Emmanuel Bettler Sandrine VadonLe Goff Catherine Moali University Lyon CNRS Tissue Biology Therapeutic Engineering Laboratory LBTI UMR5305 F69367 Lyon France Correspondence Catherine Moali Tissue Biology Therapeutic Engineering Laboratory LBTI 7 Passage du Vercors 69367 Lyon Cedex 07 France catherinemoaliibcpfr C Moali Abstract correct balance collagen synthesis degradation essential almost every aspect life development healthy aging reproduction wound healing balance compromised external internal stress signals often leads disease case ﬁbrotic conditions Fibrosis occurs context defective tissue repair characterized excessiveaberrant debilitating deposition ﬁbrilforming collagens Therefore numerous proteins involvedin biosynthesis ﬁbrillar collagens represent potential still underexploited source therapeutic targets prevent ﬁbrosis One target procollagen Cproteinase enhancer1 PCPE1 unique ability accelerate procollagen maturation BMP1tolloidlike proteinases BTPs contributes trigger collagen ﬁbrillogenesis without interfering BTP functions activities ofother extracellular metalloproteinases role achieved ﬁnetuned mechanism actionthat close elucidated offers promising perspectives drug design Finally vivo data accumulated recent years also conﬁrm PCPE1 overexpression general feature early marker ﬁbrosis review describe results presently support driving role PCPE1 inﬁbrosis discuss questions remain solved validate use biomarker therapeu tic target C2112021 Authors Published Elsevier BV open access article CC BYNCND license tivecommonsorglicensesbyncnd40 Introduction Fibrillar collagens abundant proteins human body biosynthesis criticalpathway controlling development growth homeostasis aging Fibrillar collagens numerous regulators synthesis anddegradation also represent potential targets inseveral diseases especially derived altered collagen turnover latter include limited defective tissue repair 12 cer3and osteoarthritis 4 focus ﬁbrosis general term referring common pathogenic outcome great diversity uncontrolled tissue repair responses leading aber rant accumulation extracellular matrix ECM 5 Collagens abundant components ﬁbrotic lesions known responsible tissue stiffening impaired function potentially leading death vital organ affected Despite intense efforts scientiﬁccommunity identify relevant druggable protein targets alleviate deleterious effects ﬁbrosis drugs demonstrated efﬁ cient direct antiﬁbrotic activity 5 key reg ulator collagen ﬁbrillogenesis protein named procollagen Cproteinase enhancer1 PCPE1 attracts attention PCPE1 Research Article 00222836 C2112021 Authors Published Elsevier BVThis open access article CC BYNCND license licensesbyncnd40 11 2021 100062 Page 2 potent speciﬁc enhancer ﬁbrillar collagen proteolytic maturation ratelimiting step colla gen ﬁbrillogenesis review show addition prominent role PCPE1 collagenﬁbrillogenesis speciﬁc mechanism action expression pattern closely matches collagen fact relatively dispensable tissue homeostasis players collagen synthesis also make promising target treatment prevention ofﬁbrotic disorders PCPE1 collagen ﬁbrillogenesis Fibrillar collagens usually classiﬁed major collagens II III minor collagens V XI collagen types based relative abundance common view thatminor ﬁbrillar collagens coassemble majorﬁbrillar collagens regulate ﬁbril growth 67T h classiﬁcation take account recently discovered members ﬁbrilformingcollagens collagens XXIV XXVII exhi bit restricted expression pattern pro duce ﬁbrils distinct characteristics 89 Collagens V XI form heterotrimers composed two three different polypeptide chains collagens II III form homotrimers composed ofthree identical chains 1011 notable exception normal cartilage ECM mainly consists ﬁbrils made collagens II XI theECM connective tissues usually composed ofheterotypic ﬁbrils collagens III V present various proportions 10 Collagen major ﬁbrillar component collagen III ismost abundant blood vessels collagen V cornea 712 three collagen types inter dependent lack one collagen broadconsequences ﬁbrillogenesis 1314 various steps leading individual collagen chains ﬁbrils well described formajor minor collagens 15 pathway starts synthesis collagen precursor molecules also known procollagens undergoseveral posttranslational modiﬁcations eg prolineand lysine hydroxylations assemble tri mers stage trimeric procollagen molecules kept soluble form charged Nand Cterminal domains called propeptides secretion extracellular environment propeptides cleaved speciﬁc proteolyticenzymes ﬁbrillogenesis occur Fig 1 Fibril formation supposed spontaneous process observed vitro 16 several addi tional protein partners also involved vivo obtain speciﬁc ﬁbril characteristics best ﬁt collagen tissue function Among partners FACITs ﬁbrilassociated collagens interruptedtriple helices SLRPs small leucinerich proteo glycans play major roles regulating ﬁbril diame ter spacing interactions 717 ﬁnal step ofﬁbrillogenesis stabilization collagen net work formation intermolecular crosslinks process initiated lysyl oxidases LOX LOXL 18 proteolytic enzymes cleave procollagen propeptides known procollagen N C proteinases PNPs PCPs Ten differentproteinases belonging astacin ADAMTS disintegrin metalloproteinase thrombospondin motifs SPC subtilisinlikeproprotein convertase subgroups cleave atleast one propeptide least one ﬁbrillar collagen 1922 speciﬁc interest bone morphogenetic protein1 BMP1tolloidlikeproteinases BTPs 22 form group four astacinlike proteinases comprising BMP1 mTLD mammalian tolloid two splicing variants ofthe BMP1 gene mTLL1 2 mam malian tolloidlike 1 2 encoded two additional genes TLL1 andTLL2 main enzymes charge Cterminal mat uration ﬁbrillar collagens 23 important proteolytic event trigger ﬁbrillogenesis 16 Fig 1 also cleave Ntermini minor ﬁbrillar procollagens V XI releasing ﬁrst thrombospondinlike Nterminal TSPN domain a1 chain leaving Npropeptide attached main triple helix 212426 addition process SLRPs decorin biglycan mimecanosteoglycin byremoving short sequence Nterminus 2729 partial collagen V XI N propeptide retention SLRP binding ﬁbrilsare recognized key mechanisms control ﬁbrillateral growth 7 Finally BTPs process lysyl oxidase members LOX LOXL 3032 thereby promoting activation formation covalent crosslinks collagen monomers Fig 1 PCPE1 ﬁrst described Adar colleagues 1986 contaminant PCP preparations 33 observed capable signiﬁcantly increasing procollagen Cterminal processing reason name pro collagen Cproteinase enhancer PCPE often used commonly found abbreviation PCOLCE kept gene name PCOLCE localized region chromosome 7 contains COL1A2 gene 34 leads 50 kDa glycoprotein composed two Nterminal CUB complement Uegf BMP1 domains one netrinlike NTR domain separated long linker Fig 1 B Homologues PCPE1 rather ubiquitous vertebrates amino acid sequences well conserved exception linker sequence 3436 human mouse proteins linker prone proteolysis canbe cleaved vitro wide range proteases including trypsin 37 plasmin 38M P 2 39 meprins 40 Thus proteolytic fragments corre sponding CUB1CUB2 NTR domainsP Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 2 Page 3 detected vivo cell culture 33384142 addition proteolysis human PCPE1 within CUB1 reported action soluble ADAM17 43 cleavage seems less predominant Interestingly PCPE1 speciﬁc procollagen maturation found stimulatethe Cterminal processing procollagens II III BTPs 334445 hints could also promote Cterminal maturation ofthea2 chain procollagen V supernatant mouse embryonic ﬁbroblasts 46but never conﬁrmed vitro theoretically pos sible a2 chain included heterotrimer discussed contrast Nterminal removal TSPN domain procollagen V a1 chain BTPs shown enhanced PCPE1 47 although less conclusive datahad ﬁrst obtained probably presence contaminating PCPE1 procolla gen preparation 44 extent stimulation seems somewhat lower Cterminal processing events although pre cisely quantiﬁed Also mechanism N terminal enhancement well understood forthe moment discussed Speciﬁcity procollagen maturation however striking feature PCPE1 despite theevergrowing list reported BTP substrates224850 cleavage event seems affected PCPE1 lack effect PCPE1 thus demonstrated BTP substratesinvolved collagen ﬁbrillogenesis osteo glycin LOX also ECM components processed BTPs procollagen VII laminin 332 dentin matrix protein1 dentin 3P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 4 sialophosphoprotein growth factor antago nists inactivated BTPs chordin 445152 PCPE1 expression high tissues rich collagen bones tendons skin cornea abundance lower collagen content less dominant 34375354 early studies protein detected brain liver barely detected heart kidneys 37 tempered later studies showed PCOLCE RNA derived protein relatively high heart 4555 Interest ingly contrast described Bmp1 n Tll1null mice die around birth even 255657 Pcolce null mice viable fertile show obvious defects 46 However closer inspection bones tendonsrevealed collagen ﬁbrils abnormal irregular ﬂuted shapes 46 left femora analysed transmission electronmicroscopy broadening branching ﬁb rils also observed results macroscopic alterations cortical trabecular bone geometries explained compensatory mechanism inferior material properties 46T h e importance Pcolce gene efﬁcient tissue repair also demonstrated several models ofcorneal injury characterized less pronounced delay wound closure KO mice 54 results discussed detail overall seem relate relatively mild phenotype compared effect mutations genes encoding collagenchains BMP1 enzymes involved collagen synthesis 58 Notably human genetic dis ease seems associated mutations PCOLCE Another human PCPE protein described 2000 shares 43 identity PCPE1 domain compositionFig 1 B called PCPE2 corresponding gene PCOLCE2 4559 F r mt h e studies analysed PCPE2 activity seems endowed ability increasethe Cterminal processing procollagen II BMP1 45 less clearly procollagen 60 PCPE2 also linked high densitylipoprotein HDLcholesteryl ester uptake atherosclerosis 6162 Finally found Pcolce2 null mice protected cardiac ﬁbrosis model transverse aortic constriction63 However since data PCP PNP enhancing activity possible involve ment ﬁbrosis scarce decided tofocus PCPE1 Structure mechanism action PCPE1 PCPE1 secreted protein containing multiple posttranslational modiﬁcations 3464 deco rated sialylated Nglycosylations may differ healthy diseased states resulting complex migration pattern isoelectric focusing IEF experiments 456566 w glycosylation sites predicted Nterminal one seems functional absence inducing lower protein stability 67but impact PCPE1 activity 68 mature protein also contains 14 cysteines correct disulﬁde bondingis necessary activity 69 modiﬁcations phosphorylations myristoylations detected predicted 5970 may con tribute complex pattern observed IEF PCPE1 monomer solution ﬁrst lowresolution structural data showed elongated molecule 150 C23Ai nl e n g h 71 ﬁnding somewhat unexpected since CUB NTR domains different isoelec Fig 1 Main extracellular steps collagen ﬁbril formation domain structure BTPs PCPEs secretion procollagens remain soluble processed N Cproteinases remove N andCpropeptides NPs CPs BTPs play major role maturation steps charge cleaving Cpropeptides collagens II III also process Cterminus a1 a2 chains procollagens V XI although SPCs might act a1 chains Finally BTPs mature Nterminus a1 chain procollagens V XI proteolytic event preserves large part Npropeptide incorporationinto ﬁbrils protrudes ﬁbril surface inhibits ﬁbril lateral growth PCPE1 enhances Cterminal maturation collagens II III lesser extent Nterminal maturation a1 chain collagen V BTPs control aspects collagen ﬁbrillogenesis proteolytic maturation decorin biglycan andosteoglycin SLRPs interact collagen ﬁbrils regulate diameter spacing also activate lysyl oxidases LOX LOXL thereby triggering formation crosslinks collagen monomers increase ﬁbril stability B Domain composition BTPs PCPEs BMP1 mTLD splice variantsdiffering presence short Cterminal sequence BMP1 one additional EGF two additional CUB domains mTLD mTLL1 mTLL2 domain structures similar mTLD BTPs synthesized proenzymes activated SPCs site indicated arrowhead secretory pathway catalytic activityis conferred astacinlike domain domains contribute regulate substrate speciﬁcity PCPE1 PCPE2 domain composition two Nterminal CUB domains Cterminal NTR domain connected long linker CUB domains PCPE1 proteolytically released site indicated arrowheadand retain full enhancing activity vitro P propeptide3 4P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 5 tric points around 5 individual CUB domains 95 NTR whereas fulllength protein rather neutral 6569 suggesting possible interactions two ends molecule original puriﬁcation protocol PCPE1 mouse ﬁbroblast supernatants 3364 involved use Sepharose column coupled Cpropeptide procollagen CPI PCPE1 co eluted column socalled PCP already suggesting strong afﬁnity CPI andorthe protease Interestingly although procedurealso enabled copuriﬁcation shorter 36 kDa fragment corresponding CUB domains Fig 1 B latter fulllength PCPE1 separated protease size exclusion chromatography 336472 ﬁrst indication NTR domain PCPE1was probably necessary interaction enhancer protease ﬁnding later conﬁrmed surface plasmon resonanceexperiments 73 even though interaction remains weak K 100 nM PCPE1 devoid catalytic activity already mentioned able tospeciﬁcally stimulate CP removal ﬁbrillar procollagens II III 444564 four BTPs 25457475 PCPE1 nanomolar afﬁnity procollagen molecules 7678 kinetic studies shown increase catalytic efﬁ ciency BMP1 factor 15 procollagen Iand factor 12 miniprocollagen III 6879 note increase catalytic efﬁciency derives increased afﬁnity theenzyme procollagen substrate theincreased turnover number hydrolysis reaction Several studies demonstrated enhancing activity PCPE1 provided CUB domains 33647576 due direct strong calciumdependent interaction procollagenCPs K D3 0n 7578 mutagenesis studies deletion domainswapping mutants observed contiguousCUB1 CUB2 domains necessary sufﬁcient PCPE1 activity 76 led isolation complex formed CUB1CUB2and CPIII ﬁrst analysed small angleXray scattering SAXS 68 derived low resolution structure complex revealed CUB1CUB2 binds Nterminalstalk regionof CPIII 80 close BTP cleavage site conﬁrmed previously evidenced intriguing 11 PCPE1 monomerprocollagen trimer stoichiometry 356977 recent crystal structure complex 81 gave additional informa tion unveiled key determinants mechanism action PCPE1 Fig 2 shows single PCPE1 molecule winds around CPIII tri mer CUB domain interacting mainly speciﬁc procollagen chain eg Fig 2 CUB1 chain CUB2 chain B complex isstabilized around two calcium binding sites CUB1 CUB2 interactions two con served distinct CP lysines one procol lagen chain upper left inset Fig 2 essential PCPE1 binding therefore activity 356881 Importantly mode action mobi lizes two procollagen chains simultaneously precluding binding second PCPE1 molecule Also interesting note conserved lysi nes found chains major ﬁbrillar procollagens a2 chain procollagen V chains minor ﬁbrillar procollagens 80 making unlikely PCPE1 modulates C terminal maturation BTPs However cannotbe excluded alternate mechanism play collagens structure also shows upon CUB1CUB2 binding stalk region CPIII trimer distorted end chain pulled groove CUB domains TheBMP1 active site small accommodate one procollagen chain 82 loss symmetry offers two possibilities protease bind procollagenPCPE1 complex Separated chain chain B C could become accessible enter enzyme active site Fig 2 B C BMP1 catalytic domain could bind directly locally unraveled chain Fig 2 Molecular modelling favors last mechanism since would create new interaction surface PCPE1 protease 81 contribute previously observed decrease K M6879 ﬁrst chain cleaved sequential cleavage remaining chains probably facilitated independently presence PCPE1 noted current model include BMP1 tolloid noncatalytic domains exact role remains determined BMP1 CUB EGF domains shownto necessary full enhancement PCPE1 515274 unpublished results implies direct interaction PCPE1and protease involved one stage cat alytic process interaction BMP1 PCPE1 actually weak fulllengthenhancer null CUB1CUB2 687374 ti probably strengthened presence pro collagen molecule even exact details threepartner interaction presently unknownThe involvement protease auxiliary domains also supported fact PCPE1 enhance cleavage procollagen III byanother family PCPs meprins 2040 h similar astacinlike catalytic domain CUB EGF domains 40 Instead PCPE1 inhibits meprinmediated release CPIII probablybecause binding procollagen III hinders pro tease access cleavage site role NTR domain PCPE1 less directly connected enhancing mechanism 5P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 6 still important domain homologous tissue inhibitors ofmetalloproteinases TIMPs 83 released proteolytically However early report suggesting weak inhibitor matrixmetalloproteinases 38was conﬁrmed later studies 3673 contrast NTR domain strongly interact heparin heparan sulfateproteoglycans HSPGs ie syndecans1 2 4 mediates PCPE1 attachment cell sur face 69738485 vitro presence heparin induces superstimulation procollagen pro cessing increase PCPE1 enhancing activity around twofold NTRdomain attached CUB domains 73 Since procollagens BTPs also able interact HSPGs PCPE1 may contribute forming largeprotein complexes cell surface Fig 2 Current models procollagen Cterminal maturation complex Starting crystal structure CPIII complex CUB1CUB2 region PCPE1 PDB code 6FZW 81 modelling used extend chains pink B yellow C grey procollagen III towards Ctelopeptide region collagen triple helix see 81for details Fulllength PCPE1 green rebuilt using YASARA homology modeling based UniprotSwissProt sequence Q15113 PDB code 6FZW CUB1CUB2 PDB code 1UAP forthe NTR domain YASARA also used successively model BMP1 catalytic domain BMP1 cat PDB code 6BSL blue interaction chain chain B B chain C C procollagen III Cyan spheres represent calcium ions yellow spheres zinc ions Rendering obtained using UCSF ChimeraX 178 inset shows closeup view interface PCPE1 procollagen III two procollagen lysines K1 K2 involved interaction highlighted grey discussed text model shown likely Note NTR domain PCPE1 shown give full view protein idea volume occupied bythis domain known could interact partners complex interpretation references colour ﬁgure legend reader referred web version article 6P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 7 matrix anchoring NTR domain would allow optimal orientation CUB domains maximal activity line PCPE1 also found interact ﬁbronectin 84 ﬁbulin4 86 thrombospondin1 87 involved collagen supramolecular maturation Enhancement PCP activity could also ampliﬁed presence secreted frizzled related protein 2 sFRP2 sFRP2 described another enhancer procollagen Icleavage BTPs 88 even activity protein alone remains highly controversial 528990 recently reported sFRP2 able interact mouse PCPE1 bothproteins could act synergy increase procolla gen processing vitro 91 Indeed Sfrp2 knockout mice viable show anymajor defects 92 simultaneous knockdown ofSfrp2 andPcolce embryonic lethal cultures mouse embryonic ﬁbroblasts derived thesemice show signiﬁcant decrease collagen matu ration Similarly double knockdown Sfrp2 Pcolce zebraﬁsh led strongly dorsalized phe notype decreased procollagen processing andsurvival limited 72 h mechanism unclear seems involve CUB domains PCPE1 frizzled domain sFRP2 partnershave reported PCPE1 including b2 microglobulin 93 laminin111 endostatin frag ment collagen XVIII collagen IV collagenVI87but functional implications inter actions still require investigation Finally recently shown ﬁbroblasts production secretion cell surfacelocalization PCPE1 boosted ascorbic acid vitamin C 94 essential cofactor cor rect hydroxylation folding secretion procollagens absence evidence presence hydroxyprolines PCPE1 authors suggest effect ascorbic acid PCPE1 indirectand could derive enhanced cosecretion procollagens early association would facilitate efﬁcient subsequent extracellular procollagen maturation Whether PCPE1 could also act procollagen chaperone debatable early report showing PCPE1 binds triplehelix 45 could conﬁrmed 78 known sole binding CP procollagens 78could signiﬁcant stabilizing effect Also presence PCPE1 CUB1CUB2 ﬁbrillogenesis seem affect kinetics ﬁbril formation type ﬁbrils formed 4675 indicating role enhancer probably ends procollagen processing Involvement PCPE1 tissue repair ﬁbrosis described ﬁbrosis mainly deﬁned aberrant tissue accumulation extracellular matrix components 59596 among ﬁbrillarcollagens III abundant triggered great diversity acute chronic injuries ranging apparently benign skin wounds leading hypertrophic scars fewweeks chronic hypertension causing myocardial ﬁbrosis heart failure several years silent remodelling ﬁbrosis beneﬁcial reparativecomponent wound healing tissue repair initial phase chronic uncontrolled ﬁbrosis becomes highly pathogenic impairs normalorgan function 97 Main players ﬁbrosis myoﬁbroblasts derive different cell types depending organ share similar features high contractility ability secrete largeamounts ECM proteins 9899 cells required allow tissue repair due persistent activating mechanical biochemical factors theyfail leave injured area survive beyond normal phase tissue healing continue syn thesize ECM Fibrosis principally refers excessive ECM accumulation internal organs heart lung kidney liver However tissues wherethe ECM content already high normalconditions skin cornea ﬁbrosis also reﬂect abnormal organization ECM network limited increase total ECMcontent speciﬁc potent regulator collagen ﬁbrillogenesis PCPE1 early considered potential contributor ﬁbroticdisorders 100102 However recent years accumulation data various types patient samples animal models hasmade evident strong link betweenﬁbrosis PCPE1 overexpression results described show upregulation PCPE1 observed major organs knownto develop ﬁbrosis Cardiac ﬁbrosis Cardiac ﬁbrosis associated cardiovascular diseases CVDs one themain factors predispose heart failure103104 heart myocardial stiffness leads mechanical electrical vasomotor dysfunc tions 105 typical features heart failure Myocardial infarction MI hypertension coronary artery disease valvular lesions examples CVD trigger tissue response injury andoften lead aberrant tissue remodelling excessive accumulation ECM CVDs MI damaged cells replaced byECM scar formed mechanismoften referred replacement reparative ﬁbro sis conditions affecting heart dilated cardiomyopathy hypertension morea reactive perivascular interstitial ﬁbrosis develops ie diffuse accumulation collagen myocytes 103106 Although patho physiological mechanisms leading ﬁbrosis placement reactive may differ common 7P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 8 effectors involved include ﬁbroblasts myoﬁbroblasts components renin angiotensinaldosterone system transform ing growth factor b1 TGF b196104107 context interesting note treatment adult rat heart ﬁbroblasts 25 ng ml TGF b1 shown increase amount PCPE1 culture medium factor around 2 102 study Pcolce mRNA secre tion PCPE1 protein found modestlybut signiﬁcantly increased around 15fold thepresence 10 nM aldosterone Also spironolac tone aldosterone receptor antagonist restored basal level Pcolce mRNA regulated 3fold rat model myocardial infarc tion coronary artery ligation 100 Normaliza tion presence spironolactone alsoobserved protein level conﬁrming aldos terone directly stimulates PCPE1 expression Fol lowing seminal study establishing PCPE1 expression induced MI ﬁnding conﬁrmed reports 108109 Atorvastatin cholesterollowering agent among prescribed drugs world also proved efﬁcacyin counteracting increased expression PCPE1 rat model MI 109 Similarly rosu vastatin reduced myocardial ﬁbrosis Pcolce mRNA mouse model metabolic syndrome induced deﬁciency leptin LDL receptor 110 Pressure overload secondary chronic hypertension another welldescribed cause cardiac ﬁbrosis induced animalmodels continuous subcutaneous infusion ofangiotensin II potent vasoconstrictor upstream regulator aldosterone production ﬁrst reports showing PCPE1 ismore abundant mouse heart angiotensin II treatment 111112 relationship angiotensin II cardiac ﬁbrosis PCPE1 induction recently conﬁrmed extensive study combining effect angiotensin II synthase inhibitor rats 113 nt h sm e l PCPE1 protein increased 6fold heart tissue level lesser extent circulation also colocalized ﬁbrotic areas themyocardium Notably study themodel MI described excel lent correlation PCPE1 protein quanti ﬁed heart immunoblotting amountof collagen measured immunoblotting Sirius Red staining r 082 092 100113 Another leading cause reactive ﬁbrosis chronic hypertension aortic valve stenosis common valvular disease Western countries great interest establish linkbetween disease PCPE1 studyby Beaumont colleagues 114 analysed myocardial samples interventricular sep tum cohort 28 patients versus 10 controlsamples westernblotting Although data arenot shown manuscript authors report marked increase PCPE1 levels patients 11fold patients stratiﬁed severe less severe ASPCPE1 also abundant sev ere cases Finally PCPE1 appeared well correlated collagen volume fraction toa lesser extent TGF bexpression samples agreement induction PCPE1 context left ventricular pressureoverload Pcolce mRNA also shown ele vated murine models transverse aortic con striction 115 ascending aortic banding leading dilated cardiomyopathy 116 generally PCPE1 also used assess myocardial ECM remodelling time together collagens III thecrosslinking enzyme lysyl oxidase regulation example demonstrated MI sedentary rats compared MI inexercised rats 108 subtotal nephrectomy rats 117 ischemiareperfusion injury mice 118 pigs 119 results demon strate PCPE1 overexpression broadly overlaps collagen overexpression suggest central role PCPE1 replacement interstitial ﬁbrosis heart Liver ﬁbrosis second wellstudied ﬁbrotic condition relation PCPE1 hepatic ﬁbrosis liver main causes ﬁbrosis chronic viral infections drug alcohol consumption andmetabolic disorders NASH nonalcoholic steatohepatitis elicit chronic inﬂammation lead activation effectorcells mainly hepatic stellate cells HSCs 120121 mouse NASH liver example ﬁbrogenic pathway shown enriched witha 3fold increase COL1A1 COL1A2 COL3A1 andPCOLCE transcripts 122123 Liver ﬁbrosis often develops cirrhosis severallifethreatening complications portal hypertension 1997 Ogata e ta l carried ﬁrst experiments suggesting link liver ﬁbrosis elevated PCPE1 expression showedthat HSCs derived cirrhotic rat livers obtained 7 weeks CCl 4intraperitoneal injections higher Pcolce RNA content normal liver HSCs 101 similar observation made endothelial cells freshly isolated cirrhotic rats 124 ﬁndings conﬁrmed directly cirrhotic liverswhere RNA protein detected 101 whereas PCPE1 remained undetectable normal liver 3437101 recently expression PCPE1 monitored time mice onset ﬁbrosis 6 weeks CCl 4treatment liver recovery treatment wasstopped 125 analysis revealed amounts circulating tissue PCPE1 closely 8P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 9 reﬂected ﬁbrosis severity 9fold increase tissue level quantiﬁed westernblotting end CCl 4injections peak PCPE1 plasma concentration 60 higher normal time point Furthermore PCPE1 expression fell basal levels end recovery period showing reversibility theupregulation upon termination proﬁbrotic stimulus another study rats comparing oral administration CCl 4or two proﬁbrotic chemicals short period 5 days compounds known cause nonﬁbrotic liver injury Pcolce found differentially expressed gene among set 67 selected ﬁbrogenic genes 126 result suggested expression pattern speciﬁc ﬁbrotic phe notype upregulation could detectedearly induction ﬁbrogenic response cardiac ﬁbrosis Pcolce beginning used evaluate ﬁbrotic status liver andthe efﬁcacy antiﬁbrotic compounds various preclinical models 127128 Despite rather consistent results obtained animal models conclusions availablestudies dealing patient samples presently rather confusing ﬁrst study comparing PCPE1 plasma concentration ﬁve healthy controls andﬁve patients liver ﬁbrosis caused hepatitis B C infection showed mean level circulating PCPE1 higher liver ﬁbrosisgroup although remained statistical signiﬁcance due small size cohort 129 contrast compared healthy individuals plasma concentration PCPE1 lower ina cohort 126 patients diagnosed chronic hepatitis B least 6 months thus indicating negative correlation ﬁbrosis stage 130 n addition huge difference measured PCPE1 concentrations two studies basal levels control subjects around 300 ngmlin129 agreement measure ments PCPE1 plasma concentration 66131 versus 45 ngml 130 questions reli ability commercial ELISA kits used detect PCPE1 Pulmonary ﬁbrosis Fibrosis also characteristic many respiratory diseases induced environmental pollutants infections including tuberculosis 132 COVID19 133 immune diseases certain medications Another common type lung ﬁbrosisis idiopathic pulmonary ﬁbrosis IPF chronic progressive interstitial lung disease unknown ori gin often fatal survival time lessthan 5 years diagnosis 134 character ized alterations cellular composition ECM accumulation patchy scarring causeirreversible damage lung structure function leading respiratory failure 135 recent years matrisome normal diseased lung extensively described 136137 PCPE1 found compo nent normal lung complete set dataconcerning expression lung ﬁbrosis derives proteomic study performed Schiller colleagues classical mouse model lungﬁbrosis induced bleomycin 136 ﬁrst inter esting ﬁnding solubility proﬁle PCPE1 signiﬁcantly altered upon bleomycintreatment global increase protein solubility suggesting loss potential binding part ners 87 ﬁbrotic lung ECM Despite increased solubility PCPE1 detected inthe bronchoalveolar lavage ﬂuid BALF proteome mice terms kinetics abundance PCPE1 shown peak days 3and 14 bleomycin administration correspond ing ﬁbrogenic phase diminish recovery phase maximum foldchange 27 somewhat lower mod els cardiac liver ﬁbrosis described characteristic also observed patientswhen freshly extracted IPF ﬁbroblasts compared normal lung ﬁbroblasts 138 IPF lung biopsies compared control lung biop sies RNA 139 protein level 140 h suggests PCPE1 might less directly neces sary progression pulmonary ﬁbrosis cardiac liver diseases Kidney ﬁbrosis Chronic kidney disease CKD mainly consequence diabetes hypertension glomerulonephritis highly prevalent adult population common pathway CKD isﬁbrosis ultimately lead endstage kidney failure ECM accumulating glomeruli glomerulosclerosis andor thetubulointerstitial space renal interstitial ﬁbrosis 141 PCPE1 expression kidney low normal conditions 3437 seems increase progression CKD First PCOLCE gene found located close proximity single nucleotide polymorphism associated development ofdiabetic kidney disease included panel 226 transcripts correlation kidney function quantiﬁed estimatedglomerular ﬁltration rate eGFR analysed 142 moderate signiﬁcant inverse correlation observed PCOLCE expression eGFR glomeruli indicating increased expression PCPE1 kidney function decreased contrast correlation PCOLCE transcript kidney function tubules Furthermore mean serum level PCPE1 measured ELISA 76 higher separate cohort 131 CKD patients comparedto 34 healthy controls 131 note highest recorded serum concentration 325 ngml 9P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 10 control group 840 ngml patient group albeit large variations observed groups Finally circulating PCPE1 also inver sely correlated glomerular ﬁltration rate andpositively correlated body mass index remains established consolidate present data direct link PCPE1 levels histological evidence kidney ﬁbrosis Ligament muscle ﬁbrosis Like organs described ligaments muscles affected injury activate wound healing response somecases healing result scar formation ﬁbrosis Thus semiquantitative mRNA analysis targets related collagenﬁbrillogenesis rabbit model ligament injury scarring showed PCOLCE transcript highest level upregulation after3 weeks compared BMP1 LOX TGFB1 transcripts 143 went still somewhat higher normal levels 14 weeks behaviour differed substantiallyfrom progression observed normal liga ment development could explain ligaments often fail regenerate ﬁeld inherited muscle diseases Duchenne muscular dystrophy DMD known lead skeletal muscle degeneration andnecrosis inﬂammation ﬁbrotic remodelling144 Interestingly PCPE1 expression well characterized widelyused model DMD mdx mouse spontaneous mutation dystrophin gene develops mild form disease ﬁbrotic diaphragms mdx mice collected 4 85 months age overall increase PCPE1 detected immunoblotting immunoﬂuorescence quantiﬁed seemed follow markedincrease collagen 125 Notably similarly observations made models cardiac liver ﬁbrosis 100113125 PCPE1 collagen also colocalized diaphragm tissue Finallythis study showed elevation PCPE1 levels mdx mouse plasma comparable observed Npropeptide collagen IIIPIIINP established marker ﬁbrosis 145 Another group analysed link PCPE1 muscle ﬁbrosis OPMD oculopharyngealmuscular dystrophy genetic disorder ﬁrst affecting muscles eyelid throat proximal limbs due polyalanine expansion atthe Nterminus PABPN1 polyAbindingprotein nuclear 1 protein results point completely novel mechanism mutant PABPN1 entraps PCPE1 nuclear aggregatesleading exhaustion ECM 146 ECM depletion nuclear colocalization PABPN1 aggregates observed symptomatic OMPD patient muscle biopsies mouse model disease observationsare accompanied signiﬁcant reduction PCOLCEPcolce mRNA symptomatic presymptomatic OPMD patientsmice com pared agematched controls Importantly themechanism PCPE1 sequestration nucleus seems shared another inherited muscle disease myotonic dystrophy type 1 withDMD facioscapulohumeral muscular dystrophy 146 study reveals diseasespeciﬁc mechanisms also play role challengethe general trend PCPE1 overexpression inﬁbrosisrelated conditions Corneal scarring cornea also exposed different types injuries refractive surgery physical traumas burns infections Due speciﬁc organization collagen networkrequired maintain corneal transparency 7 defects corneal wound healing lead persistent nontransparent scars associated loss ofvisual acuity 147 Soon discovery PCPE1 shown highly expressed cornea 37 recently Malecaze et al demonstrated increased theRNA level days 14 28 murine model fullthickness excision leading scarring corneal stroma epithelium 53T h e protein detected immunostaining also seemed substantially abundant stroma trend qualitatively conﬁrmed four human cor neal scars various etiologies 53 subsequent study extended results murine mod els corneal injuries 54 Five days alkali burn PCPE1 seemed rather decreased wound area highly concentrated epithelialstromal junction juxtaposed burnzone Another model epithelial abrasion led astronger immunoﬂuorescence signal PCPE1 stroma day 5 intriguingly pre ceded transient accumulation proteinjust beneath basement membrane days 1 3 various models lack Pcolce change grade opacity delayed epithelial closure neutrophil recruit ment promoted angiogenesis 54 mecha nisms underlying observations presentlynot understood Skin scarring Hypertrophic scars HTSs keloids common manifestations skin ﬁbrosisThey occur wound healing response triggered activating signals fail disappear Whereas normal scars usually appearas ﬁne ﬂat lines regain 80 original skin tensile strength HTSs raised erythematous sometimes pruritic painful andcan cause contractures affecting mobility However remain restricted injury area 10P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 11 contrast keloid scars grow outside injury boundaries evolve benign dermal tumors usually recur excision 148149 Like ﬁbrotic disorders TGF bsignaling largely demonstrated critical regulator skin scarring 150151 context interest ing note addition 10 ngml TGF b1t normal human dermal ﬁbroblasts effect PCPE1 synthesis 152 unpublished results contrast positive effect describedfor heart ﬁbroblasts 102 suggesting effect growth factor ﬁbroblasts depends tis sue origin best knowledge effect TGF b1 synthesis PCPE1 HTS keloid ﬁbroblasts never directly tested data suggesting PCPE1 could still important driver collagen aberrantaccumulation skin scars First secreted PCPE 1 protein seems signiﬁcantly abundant tenfold cultures HTS ﬁbroblastsas assessed immunoblotting compared normal ﬁbroblasts 153 Second PCOLCE mRNA upregulated skin biopsies HTSs andkeloids 154155 Finally treatment ﬁbroblasts extracted type skin scars rapa mycin mTOR inhibitor known hinder ﬁbroblast proliferation ECMcollagen synthesisdecreased PCOLCE transcription 58 69 normal HTS keloid ﬁbroblasts 155 PCPE1 biomarker ﬁbrosis studies described suggest PCPE 1 could excellent tissue marker revealﬁbrotic lesions Tissue biopsies remain widely used diagnosis disease monitoring ﬁeld ﬁbrosisrelated diseases despite theirinvasiveness possible sampling errors However already established collagen speciﬁc histological methods detect ﬁbrosis intissue sections unlikely PCPE1 immunostaining would bring addedvalue promising therefore development ofmethods allowing detection noninvasive approaches quantitation easilyaccessible body ﬂuids search new biomarkers ﬁeld ﬁbrosis extremelyactive either reliable sensitive markers presently missing speciﬁc insufﬁcient contextPCPE1 strong potential even several steps validated clinical use considered presently well established PCPE1 found human serum plasma easily detected quantiﬁed using several techniques immunoblotting ELISA andmass spectrometry 66113129131156 Accord ing present literature public databases PCPE1 also found cerebrospinal ﬂuid 157 160 almost undetectable saliva urine bronchoalveolar ﬂuid Even though comprehensive studies establishing relationship severity tissue ﬁbrosis circulat ing levels PCPE1 performed murine models 113125126 measuring PCPE1 human plasma also revealed elevated concen trations diseased individuals strong suspi cion liver kidney ﬁbrosis 129131 Moreover good hints PCPE1 monitoring allows early detection ﬁbrogenicpreﬁbrotic stages closely correlated ﬁbrosis severity125126136 urgent need hence strengthen patient studies orthogonal evalu ation tissue ﬁbrosis extend larger cohorts new ﬁbrotic disorders ideal biomarker speciﬁc targeted disease likely several concomitant conditions occurring parallel ﬁbrosis affectPCPE1 blood levels case closely related collagen metabolites collagen III propeptides telopeptides show variationsassociated age sex bone remodelling pregnancy 161163 Whether PCPE1 circulating levels display variations remains beanalysed already known bone disorderscan affect concentration glycosylation pat tern human serum 66 However noted truly speciﬁc biomarkers ﬁbrosis arevery rare combinations biomarkers often considered reliable 164167 ns u mary PCPE1 represents promising biomarkerof ﬁbrosis alone combination biomarkers extensive evaluation ﬁbrotic patient samples required detection implemented clinical practice PCPE1 therapeutic target prevent ﬁbrosis broadly exempliﬁed PCPE1 found larger amounts ﬁbrotic tissues normaltissues RNA protein levels exceptions show whether PCPE1 overexpression causative factor ofﬁbrosis indirect consequence theﬁbrotic environment However current knowledge direct contribution last step procollagen maturation preceding ﬁbrilformation speciﬁcity collagenrelated processes colocalization collagen several types ﬁbrotic scars mechanismof action requiring 11 ratio procollagen maximal enhancement point direct prominent contribution aberrant collagendeposition ﬁbrosis Curiously effect theabsence PCPE1 studied models corneal scarring clear positive effect collagen abundance cornealtransparency could evidenced 54 Due high content collagen cornea might best model establish PCPE1 depletion inhibition signiﬁcantly affect colla gen integration ECM models dealing 11P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 12 less collagenrich organs might infor mative Thus critically missing point combination model cardiac kidney liver ﬁbrosis PCPE1 overexpression deﬁciency inhibition demonstrate modula tion PCPE1 activity signiﬁcantly impact collagen volume fraction function theseorgans Nevertheless already speculate great advantage targeting PCPE1 reparativeﬁbrosis processes would BTPs remainactive basal level ensure minimum amount properly matured collagen ﬁbrils continue synthesized repair theinjured tissue Indeed complete blockade collagen deposition known detrimental effects normal injured adult tissues asdemonstrated analysis conditional double Bmp1 Tll1knockout mice 168170 illustrative fact BTP ablation youngadult mice leads progressive reduction thickness skin dermis neverhealing wounds 168 Another obvious strong point PCPE1 target especially contrast PCPs PNPs speciﬁcity procollagen maturation described seem affect theprocessing BTP substrates beside ﬁbrillar procollagens 445152 potential TIMPlike activity NTR domain conﬁrmed 73 procollagen speciﬁcity also implies proﬁbrogenic BTP substrates prolysyl oxidases involved regulation TGF bsignalling 2248 direct regulation PCPE1 However role matrix stiffening ampliﬁcation ﬁbrogenesis clearly demonstrated recent years171172 speculate PCPE1 also contributes ﬁbrosis increasing collagen ﬁbril density therefore tissue mechanical strains point important mention PCPE 1 speciﬁcity challenged reports suggesting possible roles protein inangiogenesis 5487173 cell proliferation 174175 RNA stabilization 176 Among role angiogenesis mostwell supportedand considered seriously First PCPE1was found belong group ﬁve ECM proteins synthesized ﬁbroblasts together collagen required promote endothelial cell lumen formation 173 Second PCPE1 strongly bind several antiangiogenic factors endostatin thrombospondin1 displays antiangiogenic properties vitro assays 5487 vivo model corneal wound healing induced alkali treatment 54 presently clear mechanism explain theseobservations remains possible control angiogenesis PCPE1 indirect conse quence role collagen maturationIn terms drug development know PCPE1 forms tight complex procollagens III 334477 Even proteinprotein interac tions known difﬁcult targets bepossible develop molecules capable binding either enhancer procollagen motifs involved interaction latter canbe considered lead efﬁcient slow procollagen maturation slightly dif ferent consequences pharmacological moleculetargeting PCPE1 would block interaction withthe CPs three major ﬁbrillar collagens II III targeting CP one procollagen would principle diminish maturation thisspeciﬁc molecule without affecting maturation procollagens Given previously described interdependence ﬁbrillar collagens 1314 latter approach would require determination collagen network cope delayed incorporation one collagen typeHowever considering high level homology CPs procollagens II III 46 identity might actually easier develop apanCP inhibitory molecule case bothstrategies similar outcomes related questions remain regarding fate unprocessed procollagens context aﬁbrosisrelated rapid procollagen synthesis combined decrease maturation efﬁciency preferred scenario would berapidly degraded MMPs ECM degrading proteases released ﬁbroblasts inﬂammatory cells Overall collagen degradationwhich thought insufﬁcient context ofﬁbrosis could beneﬁt collagen intermediates easily accessible proteolytic degradation ﬁbrilembedded highly crosslinked collagen monomers another scenario unprocessed procollagens would persist tissue could potentially trigger signallingin surrounding cells including involved resolution ﬁbrosis Along line addition CPI cultures human lung ﬁbroblasts wasearly found induce dosedependent decrease collagen synthesis 177 although result never conﬁrmed explained suggeststhat released Cpropeptides could exert negativetranscriptional feedback collagen synthesis Whether type signalling also induced CPs retained procollagens whetherthe lack CP sensing cells would rather increase collagen synthesis remains anal ysed addition previous outcomes itremains possible unprocessed partially processed procollagen molecules aberrantly incorporated newly formed ﬁbrils However Cpropeptide retention collagen ﬁbrils waspreviously observed Bmp1 C0C0Tll1C0C0mouse embryonic cell layers case PcolceC0C0cell layers 46 giving good indication 12P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 13 collagen processing intermediates become abnormally integrated ﬁbrils PCPE1 activity missing summarized Table 1 PCPE1 many clear advantages antiﬁbrotic target several questions still need addressed toconﬁrm potential Especially future work theﬁeld aim clarifying overall effect modulating PCPE1 expression activity collagen abundance organization DECLARATION COMPETING INTEREST authors declare competing ﬁnancial interests Acknowledgements work supported CNRS University Lyon Agence Nationale de la Recherche ANR grant 17CE140033 thank Jeannette Meunier Lucie Essayan LBTI Univ Lyon France theircontribution preliminary analysis PCPE1expression data ﬁbrosis David Hulmes LBTI Univ Lyon France critical reading manuscript Received 19 January 2021 Accepted 15 March 2021 Available online 20 April 2021 Keywords Fibrosis Collagen Fibrillogenesis Proteolysis Therapeutic target BiomarkerPresent address Helmholtz Institute pharmaceutical sciences Campus E8 1 66123 Saarbru cken Germany Abbreviations ADAMTS disintegrin metalloproteinase thrombospondin motifs aortic valve stenosis BMP bone morphogenetic protein CVD cardiovascular disease CKD chronic kidney disease CP Cpropeptide CUB complement Uegf BMP1 DMD Duchenne muscular dystrophy ECM extracellular matrix EGF epidermal growth factor eGFR estimated glomerular ﬁltration rate ELISA enzymelinked immunosorbent assay HDL highdensity lipoprotein HSC hepatic stellate cell HTS hypertrophic scar IPF idiopathic pulmonary ﬁbrosis LDL lowdensity lipoprotein MI myocardial infarction MMP matrix metalloproteinase mTLD mammalian tolloid mTLL mammalian tolloidlike NASH nonalcoholic steatohepatitis NTR netrin PABPN1 polyAbinding protein nuclear 1 OPMD oculopharyngeal muscular dystrophy PCP procollagen Cproteinase PCPE procollagen Cproteinase enhancerPNP procollagen Nproteinase SPC subtilisin proprotein convertase TIMP tissue inhibitor metalloproteinases TGF b transforming growthfactor b TSPN thrombospondinlike Nterminal References 1RicardBlum Baffet G Theret N 2018 Molecular tissue alterations collagens ﬁbrosis Matrix Biol 6869 122149 2Wells Nuschke Yates CC 2016 Skin tissue repair Matrix microenvironmental inﬂuences Matrix Biol 49 2536 3Nissen NI Karsdal Willumsen N 2019 Collagens cancer associated ﬁbroblasts reactive stroma relation cancer biology J Exp Clin Cancer Res 38 115 4Poole AR Kobayashi Yasuda Laverty Mwale F Kojima Sakai Wahl C ElMaadawy Webb G Tchetina E Wu W 2002 Type II collagen degradation regulation articularTable 1 Pros cons targeting PCPE1 activity prevent collagen accumulation ﬁbrosis Pros Cons PCPE1 activity signiﬁcantly increases collagen ﬁbrillogenesis Delaying procollagen processing could sufﬁcient observe signiﬁcant reduction tissue ﬁbrosis Basal collagen assembly remains possible allow tissue repair Absence PCPE1 lead Cpropeptide retention collagen ﬁbrilsConsequences possible accumulation unprocessed procollagen molecules ﬁbrosis models unknown PCPE1 highly speciﬁc collagen biosynthesis increased PCPE1 expression found sites highcollagen depositionPCPE1 unexplained role angiogenesis remains explored Structural data available facilitate drug development Proteinprotein interactions difﬁcult target smallmolecule inhibitors AntiPCPE strategies applied multiple potential indications ﬁbrosisDeleterious effects longterm PCPE1 inhibition tissue homeostasis case comorbidity eg wounds bonefractures cannot excluded 13P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 14 cartilage osteoarthritis Ann Rheum Dis 61Suppl 2 ii78ii81 5Henderson NC Rieder F Wynn TA 2020 Fibrosis mechanisms medicines Nature 587 555566 6Birk DE Fitch JM Babiarz JP Doane KJ Linsenmayer TF 1990 Collagen ﬁbrillogenesis vitro interaction types V collagen regulates ﬁbril diameter J Cell Sci 95Pt 4 649657 7Espana EM Birk DE 2020 Composition structure function corneal stroma Exp Eye Res 198 108137 8Matsuo N Tanaka Yoshioka H Koch Gordon MK Ramirez F 2008 Collagen XXIV Col24a1 gene expression speciﬁc marker osteoblast differentiation bone formation Connect Tissue Res 49 6875 9Plumb DA Dhir V Mironov Ferrara L Poulsom R Kadler KE Thornton DJ Briggs MD Boot Handford RP 2007 Collagen XXVII developmentally regulated forms thin ﬁbrillar structures distinct classical vertebrate ﬁbrillar collagens J Biol Chem 282 1279112795 10 Bella J Hulmes DJ 2017 Fibrillar collagens Subcell Biochem 82 457490 11 RicardBlum 2011 collagen family Cold Spring Harb Perspect Biol 3a004978 12 Kuivaniemi H Tromp G 2019 Type III collagen COL3A1 Gene protein structure tissue distribution associated diseases Gene 707 151 171 13 Liu X Wu H Byrne Krane Jaenisch R 1997 Type III collagen crucial collagen ﬁbrillogenesis normal cardiovascular development Proc Natl Acad Sci U 94 18521856 14 Sun Chen Adams SM Florer JB Liu H Kao WW Wenstrup RJ Birk DE 2011 Collagen V dominant regulator collagen ﬁbrillogenesisdysfunctional regulation structure function cornealstromaspeciﬁc Col5a1null mouse model J Cell Sci124 40964105 15 Myllyharju J Kivirikko KI 2004 Collagens modifying enzymes mutations humans ﬂies worms Trends Genet 20 3343 16 Kadler KE Hojima Prockop DJ 1987 Assembly collagen ﬁbrils de novo cleavage type pC collagen procollagen Cproteinase Assay critical concentration demonstrates collagen selfassembly classical example entropydriven process J Biol Chem 262 1569615701 17 Taye N Karoulias SZ Hubmacher 2020 1540 role noncollagenous extracellular matrix proteins minor collagens tendon J Orthop Res 38 2335 18 Vallet SD RicardBlum 2019 Lysyl oxidases enzyme activity extracellular matrix crosslinks Essays Biochem 63 349364 19 Bekhouche Colige 2015 procollagen N proteinases ADAMTS2 3 14 pathophysiology Matrix Biol 4446 4653 20 Broder C Arnold P VadonLe Goff Konerding Bahr K Muller Overall CM Bond JS Koudelka Tholey Hulmes DJ Moali C BeckerPauly C 2013 Metalloproteases meprinalpha meprin beta C Nprocollagenproteinases important collagen assembly tensile strength Proc Natl Acad Sci U 110 14219 14224 21 Unsold C Pappano WN Imamura Steiglitz BMGreenspan DS 2002 Biosynthetic processing proalpha 1V2proalpha 2V collagen heterotrimer bone morphogenetic protein1 furinlike proprotein convertases J Biol Chem 277 55965602 22 VadonLe Goff Hulmes DJ Moali C 2015 BMP 1tolloidlike proteinases synchronize matrix assembly growth factor activation promote morphogenesis tissue remodeling Matrix Biol 4446 1423 23 Moali C Hulmes DJ 2012 Roles regulation BMP1tolloidlike proteinases collagenmatrix assembly growth factor activation beyond Karamanos Ed Extracellular Matrix Pathobiology Signaling De Gruyter Berlin pp 539561 24 Gopalakrishnan B Wang WM Greenspan DS 2004 Biosynthetic processing Proalpha1V Proalpha2VProalpha3V procollagen heterotrimer J Biol Chem 279 3090430912 25 Pappano WN Steiglitz BM Scott IC Keene DR Greenspan DS 2003 Use Bmp1Tll1 doubly homozygous null mice proteomics identify validate vivo substrates bone morphogenetic protein 1tolloidlike metalloproteinases Mol Cell Biol 23 44284438 26 Imamura Steiglitz BM Greenspan DS 1998 Bone morphogenetic protein1 processes NH2 terminal propeptide furinlike proprotein convertase processes COOHterminal propeptide proalpha1V collagen J Biol Chem 273 27511 27517 27 Ge G Seo NS Liang X Hopkins DR Hook Greenspan DS 2004 Bone morphogenetic protein 1tolloidrelated metalloproteinases process osteoglycin enhance ability regulate collagen ﬁbrillogenesis J Biol Chem 279 4162641633 28 Scott IC Imamura Pappano WN Troedel JM Recklies AD Roughley PJ Greenspan DS 2000 Bone morphogenetic protein1 processes probiglycan J Biol Chem 275 3050430511 29 von Marschall Z Fisher LW 2010 Decorin processed three isoforms bone morphogenetic protein1 BMP1 Biochem Biophys Res Commun 391 13741378 30 Borel Eichenberger Farjanel J Kessler E Gleyzal C Hulmes DJ Sommer P Font B 2001 Lysyl oxidaselike protein bovine aorta Isolation maturation active form bone morphogenetic protein1 J Biol Chem 276 4894448949 31 Cronshaw AD FothergillGilmore LA Hulmes DJ 1995 proteolytic processing site precursor lysyl oxidase Biochem J 306 Pt 1 279284 32 Panchenko MV StetlerStevenson WG Trubetskoy OV Gacheru SN Kagan HM 1996 Metalloproteinase activity secreted ﬁbrogenic cells processing prolysyl oxidase Potential role procollagen C proteinase J Biol Chem 271 7113 7119 33 Adar R Kessler E Goldberg B 1986 Evidence protein enhances activity type procollagen Cproteinase Coll Relat Res 6 267277 14P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 15 34 Takahara K Kessler E Biniaminov L Brusel Eddy RL JaniSait Shows TB Greenspan DS 1994 Type procollagen COOHterminal proteinase enhancer protein identiﬁcation primary structure chromosomal localization cognate human genePCOLCE J Biol Chem 269 2628026285 35 Blanc G Font B Eichenberger Moreau C Ricard Blum Hulmes DJ Moali C 2007 Insights CUB domains exert speciﬁc functions sharing common fold Conserved speciﬁc features CUB1 domain contribute molecular basis procollagen Cproteinase enhancer1 activity J Biol Chem 282 1692416933 36 Liepinsh E Banyai L Pintacuda G Trexler Patthy L Otting G 2003 NMR structure netrinlike domain human type procollagen C proteinase enhancer deﬁnes structural consensus NTR domains assesses potential proteinase inhibitory activity ligand binding J Biol Chem 278 2598225989 37 Kessler E Mould AP Hulmes DJ 1990 Procollagen type Cproteinase enhancer naturally occurring connective tissue glycoprotein Biochem Biophys Res Commun 173 8186 38 Mott JD Thomas CL Rosenbach MT Takahara K Greenspan DS Banda MJ 2000 Post translational proteolytic processing procollagen C terminal proteinase enhancer releases metalloproteinase inhibitor J Biol Chem 275 1384 1390 39 Dean RA Overall CM 2007 Proteomics discovery metalloproteinase substrates cellular context iTRAQ labeling reveals diverse MMP2 substrate degradome Mol Cell Proteomics 6 611623 40 Kronenberg Bruns BC Moali C VadonLe Goff Sterchi EE Traupe H Bohm Hulmes DJ Stocker W BeckerPauly C 2010 Processing procollagen III meprins new players extracellularmatrix assembly J Invest Dermatol 130 27272735 41 Lopez B Gonzalez Beaumont J Querejeta R Larman Diez J 2007 Identiﬁcation potential cardiac antiﬁbrotic mechanism torasemide patients chronic heart failure J Coll Cardiol 50 859 867 42 Lareu RR Subramhanya KH Peng Benny P Chen C Wang Z Rajagopalan R Raghunath 2007 Collagen matrix deposition dramatically enhanced vitro crowded charged macromolecules biological relevance excluded volume effect FEBS Lett 581 27092714 43 Scharfenberg F Helbig Sammel Benzel J Schlomann U Peters F Wichert R Bettendorff SchmidtArras RoseJohn Moali C Lichtenthaler SF Pietrzik CU Bartsch JW Tholey BeckerPauly C 2020 Degradome soluble ADAM10 ADAM17 metalloproteases Cell Mol Life Sci 77 331350 44 Moali C Font B Ruggiero F Eichenberger Rousselle P Francois V Oldberg Bruckner Tuderman L Hulmes DJ 2005 Substratespeciﬁc modulation multisubstrate proteinase Cterminal processing ﬁbrillar procollagens BMP1dependent activity enhanced PCPE1 J Biol Chem 280 2418824194 45 Steiglitz BM Keene DR Greenspan DS 2002 PCOLCE2 encodes functional procollagen C proteinase enhancer PCPE2 collagenbindingprotein differing distribution expression post translational modiﬁcation previously described PCPE1 J Biol Chem 277 4982049830 46 Steiglitz BM Kreider JM Frankenburg EP Pappano WN Hoffman GG Meganck JA Liang X Hook Birk DE Goldstein SA Greenspan 2006 Procollagen C proteinase enhancer 1 genes important determinants mechanical properties geometry bone ultrastructure connective tissues Mol Cell Biol 26 238249 47 Symoens Renard BonodBidaud C Syx Vaganay E Malfait F RicardBlum Kessler E Van Coucke P Ruggiero F De Paepe 2010 Identiﬁcation binding partners interacting alpha1Npropeptide type V collagen Biochem J 433 371381 48 Anastasi C Rousselle P Talantikite Tessier Cluzel C Bachmann Mariano N Dussoyer Alcaraz LB Fortin L Aubert Delolme F El Kholti N Armengaud J Fournie P Auxenfans C Valcourt U Goff SV Moali C 2020 BMP1 disrupts cell adhesion enhances TGFbeta activation cleavage matricellular protein thrombospondin1 Sci Signal 13 49 Banerjee Andrew RJ Duff CJ Fisher K Jackson CD Lawrence CB Maeda N Greenspan DS Kellett KAB Hooper NM 2019 Proteolysis low density lipoprotein receptor bone morphogenetic protein1 regulates cellular cholesterol uptake Sci Rep 9 11416 50 Heumuller SE Talantikite Napoli Armengaud J Morgelin Hartmann U Sengle G Paulsson Moali C Wagener R 2019 Cterminal proteolysis ofthe collagen VI alpha3 chain BMP1 proprotein convertases releases endotrophin fragments different sizes J Biol Chem 294 1376913780 51 Petropoulou V GarrigueAntar L Kadler KE 2005 Identiﬁcation minimal domain structure bone morphogenetic protein1 BMP1 chordinase activity chordinase activity enhanced procollagen C proteinase enhancer1 PCPE1 J Biol Chem 280 2261622623 52 von Marschall Z Fisher LW 2010 Dentin sialophosphoprotein DSPP cleaved two natural dentin matrix products three isoforms bone morphogenetic protein1 BMP1 Matrix Biol 29 295 303 53 Malecaze F Massoudi Fournie P Tricoire C Cassagne Malbouyres Hulmes DJ Moali C Galiacy SD 2014 Upregulation bone morphogenetic protein1mammalian tolloid procollagen Cproteinase enhancer1 corneal scarring Invest Ophthalmol Vis Sci 55 6712 6721 54 Massoudi Germer CJ Glisch JM Greenspan 2017 Procollagen Cproteinase enhancer 1 PCPE 1 functions antiangiogenic factor enhances 15P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 16 epithelial recovery injured cornea Cell Tissue Res 370 461476 55 Doll Dressen Geyer PE Itzhak DN Braun C Doppler SA Meier F Deutsch Lahm H Lange R Krane Mann 2017 Region celltype resolved quantitative proteomic map human heart Nat Commun 8 1469 56 Clark TG Conway SJ Scott IC Labosky PA Winnier G Bundy J Hogan BL Greenspan DS 1999 mammalian Tolloidlike 1 gene Tll1 necessary normal septation positioning heart Development 126 26312642 57 Suzuki N Labosky PA Furuta Hargett L Dunn R Fogo AB Takahara K Peters DM Greenspan DS Hogan BL 1996 Failure ventral body wall closure mouse embryos lacking procollagen C proteinase encoded Bmp1 mammalian gene related Drosophila tolloid Development 122 35873595 58 Marini JC Forlino Bachinger HP Bishop NJ Byers PH Paepe Fassier F FratzlZelman N Kozloff KM Krakow Montpetit K Semler 2017 Osteogenesis imperfecta Nat Rev Dis Primers 3 17052 59 Xu H Acott TS Wirtz MK 2000 Identiﬁcation expression novel type procollagen C proteinase enhancer protein gene glaucoma candidate region 3q21q24 Genomics 66 264273 60 Zhu J Gardner J Pullinger CR Kane JP Thompson JF Francone OL 2009 Regulation apoAI processing procollagen Cproteinase enhancer 2 bone morphogenetic protein1 J Lipid Res 50 13301339 61 Francone OL Ishida de la LleraMoya Royer L Happe C Zhu J Chalkey RJ Schaefer P Cox C Burlingame Kane JP Rothblat GH 2011 Disruption murine procollagen Cproteinase enhancer 2 gene causes accumulation proapoAI increased HDL levels J Lipid Res 52 19741983 62 Pollard RD Blesso CN Zabalawi Fulp B Gerelus Zhu X Lyons EW Nuradin N Francone OL Li XA Sahoo Thomas MJ SorciThomas MG 2015 Procollagen C endopeptidase enhancer protein 2 PCPE2 reduces atherosclerosis mice enhancing scavenger receptor class B1 SRBImediated highdensity lipoprotein HDLcholesteryl ester uptake J Biol Chem 290 1549615511 63 Baicu CF Zhang Van Laer AO Renaud L Zile MR Bradshaw AD 2012 Effects absence procollagen Cendopeptidase enhancer2 myocardial collagen accumulation chronic pressure overload J Physiol Heart Circ Physiol 303 H234H240 64 Kessler E Adar R 1989 Type procollagen C proteinase mouse ﬁbroblasts Puriﬁcation demonstration 55kDa enhancer glycoprotein Eur J Biochem 186 115121 65 MesilatyGross Anikster Vilensky B Wolf Phillip GatYablonski G 2009 Different patterns human serum procollagen Cproteinase enhancer1 PCPE1 Clin Chim Acta 403 7680 66 OlswangKuz Liberman B Weiss Ramu E Weitzen R Vered GatYablonski G Kessler EAnikster MesilatyGross 2011 Quantiﬁcation ofhuman serum procollagen Cproteinase enhancer hsPCPE glycopattern Clin Chim Acta 412 1762 1766 67 Wang Zhong L Li Xiao Zhang R Liao DLv Wang X Wang J Xie X Chen J Wu Kang 2019 Upregulation PCOLCE TWIST1 promotes metastasis Osteosarcoma Theranostics 9 43424353 68 Bourhis JM VadonLe Goff Afrache H Mariano N Kronenberg Thielens N Moali C Hulmes DJ 2013 Procollagen Cproteinase enhancer grasps stalk Cpropeptide trimer boost collagen precursor maturation Proc Natl Acad Sci U 110 63946399 69 Moschcovich L Bernocco Font B Rivkin H Eichenberger Chejanovsky N Hulmes DJ Kessler E 2001 Folding activity recombinant human procollagen Cproteinase enhancer Eur J Biochem 268 29912996 70 Hoffert JD Pisitkun Wang G Shen RF Knepper 2006 Quantitative phosphoproteomics vasopressinsensitive renal cells regulation aquaporin2 phosphorylation two sites Proc Natl Acad Sci U 103 71597164 71 Bernocco Steiglitz BM Svergun DI Petoukhov MV Ruggiero F RicardBlum Ebel C Geourjon C Deleage G Font B Eichenberger Greenspan DS Hulmes DJ 2003 Low resolution structure determination shows procollagen Cproteinase enhancer elongated multidomain glycoprotein J Biol Chem 278 71997205 72 Kessler E Adar R Goldberg B Niece R 1986 Partial puriﬁcation characterization procollagen Cproteinase culture medium mouse ﬁbroblasts Coll Relat Res 6 249266 73 Bekhouche Kronenberg VadonLe Goff Bijakowski C Lim NH Font B Kessler E ColigeA Nagase H Murphy G Hulmes DJ Moali C 2010 Role netrinlike domain procollagen C proteinase enhancer1 control metalloproteinase activity 1 J Biol Chem 285 1595015959 74 Ge G Zhang Steiglitz BM Greenspan DS 2006 Mammalian tolloidlike 1 binds procollagen C proteinase enhancer protein 1 differs bone morphogenetic protein 1 functional roles homologous protein domains J Biol Chem 281 1078610798 75 Hulmes DJ Mould AP Kessler E 1997 CUB domains procollagen Cproteinase enhancer control collagen assembly solely effect procollagen C proteinasebone morphogenetic protein1 Matrix Biol 16 4145 76 Kronenberg VadonLe Goff Bourhis JM Font B Eichenberger Hulmes DJ Moali C 2009 Strong cooperativity loose geometry CUB domains basis procollagen C proteinase enhancer activity J Biol Chem 284 3343733446 77 RicardBlum Bernocco Font B Moali C Eichenberger Farjanel J Burchardt ER van der RM Kessler E Hulmes DJ 2002 Interaction 16P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 17 properties procollagen Cproteinase enhancer protein shed light mechanism stimulation BMP1 J Biol Chem 277 3386433869 78 VadonLe Goff Kronenberg Bourhis JM Bijakowski C Raynal N Ruggiero F Farndale RW Stocker W Hulmes DJ Moali C 2011 Procollagen Cproteinase enhancer stimulates procollagen processing binding Cpropeptide region J Biol Chem 286 3893238938 79 Moschcovich L Kessler E 2016 Data comparing kinetics procollagen type processing bone morphogenetic protein 1 BMP1 without procollagen Cproteinase enhancer 1 PCPE1 Data Brief 9 883887 80 Bourhis JM Mariano N Zhao Harlos K Exposito JY Jones EY Moali C Aghajari N Hulmes DJ 2012 Structural basis ﬁbrillar collagen trimerization related genetic disorders Nat Struct Mol Biol 19 10311036 81 Pulido Sharma U VadonLe Goff Hussain SA Cordes Mariano N Bettler E Moali C Aghajari N Hohenester E Hulmes DJS 2018 Structural basis acceleration procollagen processing procollagen Cproteinase enhancer1 Structure 26 13841392 e1383 82 Mac Sweeney GilParrado Vinzenz Bernardi Hein Bodendorf U Erbel P Logel C Gerhartz B 2008 Structural basis substrate speciﬁcity bone morphogenetic protein 1tolloidlike metalloproteases J Mol Biol 384 228239 83 Banyai L Patthy L 1999 NTR module domains netrins secreted frizzled related proteins type procollagen Cproteinase enhancer protein homologous tissue inhibitors metalloproteases Protein Sci 8 16361642 84 Weiss Brusel Rousselle P Kessler E 2014 NTR domain procollagen Cproteinase enhancer 1 PCPE1 mediates PCPE1 binding syndecans1 2and 4 well ﬁbronectin Int J Biochem Cell Biol 57 4553 85 Weiss RicardBlum Moschcovich L Wineman E Mesilaty Kessler E 2010 Binding procollagen Cproteinase enhancer1 PCPE1 heparinheparan sulfate properties role PCPE1 interaction cells J Biol Chem 285 3386733874 86 Papke CL Tsunezumi J Ringuette LJ Nagaoka H Terajima Yamashiro Urquhart G Yamauchi Davis EC Yanagisawa H 2015 Loss ﬁbulin4 disrupts collagen synthesis maturation implications pathology resulting EFEMP2 mutations Hum Mol Genet 24 58675879 87 Salza R Peysselon F Chautard E Faye C Moschcovich L Weiss PerrinCocon L Lotteau V Kessler E RicardBlum 2014 Extended interaction network procollagen Cproteinase enhancer1 extracellular matrix Biochem J 457 137149 88 Kobayashi K Luo Zhang Wilkes DC Ge G Grieskamp Yamada C Liu TC Huang G Basson CT Kispert Greenspan DS Sato TN 2009 Secreted Frizzledrelated protein 2 procollagen C proteinase enhancer role ﬁbrosis associated myocardial infarction Nat Cell Biol11 4655 89 Bijakowski C VadonLe Goff Delolme F Bourhis JM Lecorche P Ruggiero F BeckerPauly C Yiallouros Stocker W Dive V Hulmes DJ Moali C 2012 Sizzled unique among secreted frizzledrelated proteins ability speciﬁcally inhibitbone morphogenetic protein1 BMP1tolloidlike proteinases J Biol Chem 287 3358133593 90 W Zhang L Ni Zhang Z Mirotsou Mao L Pratt Dzau VJ 2010 Exogenously administered secreted frizzled related protein 2 Sfrp2 reduces ﬁbrosis improves cardiac function rat model myocardial infarction Proc Natl Acad Sci U 107 2111021115 91 Zhu Q Guo W Zhang Feng Wang X Greenspan DS Zhou L Huang GR 2019 Synergistic effect PCPE1 sFRP2 processing procollagens via BMP1 FEBS Lett 593 119127 92 Satoh W Gotoh Tsunematsu Aizawa Shimono 2006 Sfrp1 Sfrp2 regulate anteroposterior axis elongation somite segmentation mouse embryogenesis Development 133 989999 93 Morimoto H Wada J Font B Mott JD Hulmes J Ookoshi Naiki H Yasuhara Nakatsuka Fukuoka K Takatori Ichikawa H Akagi Nakao K Makino H 2008 Procollagen Cproteinase enhancer1 PCPE1 interacts beta2microglobulin beta2m may help initiate beta2m amyloid ﬁbril formation connective tissues Matrix Biol 27 211 219 94 Gohar Weiss Wineman E Kessler E 2020 Ascorbic acid promotes procollagen Cproteinase enhancer 1 expression secretion cell membrane localization Anat Rec Hoboken 303 16701679 95 Walraven Hinz B 2018 Therapeutic approaches control tissue repair ﬁbrosis Extracellular matrix game changer Matrix Biol 7172 205224 96 Weber KT 1989 Cardiac interstitium health disease ﬁbrillar collagen network J Coll Cardiol 13 16371652 97 Rockey DC Bell PD Hill JA 2015 Fibrosisa common pathway organ injury failure N Engl J Med 372 11381149 98 DeLeonPennell KY Barker TH Lindsey ML 2020 Fibroblasts arbiters extracellular matrix remodeling Matrix Biol 9192 17 99 Micallef L Vedrenne N Billet F Coulomb B Darby IA Desmouliere 2012 myoﬁbroblast multiple origins major roles normal pathological tissue repair Fibrogenesis Tissue Repair 5S 5 100 KesslerIcekson G Schlesinger H Freimann Kessler E 2006 Expression procollagen C proteinase enhancer1 remodeling rat heart stimulated aldosterone Int J Biochem Cell Biol 38 358365 101 Ogata Auster Matsui Greenwel P Geerts DAmico Fujiwara K Kessler E Rojkind 1997 Upregulation type procollagen Cproteinase enhancer protein messenger RNA rats CCl4 induced liver ﬁbrosis Hepatology 26 611617 102 Shalitin N Schlesinger H Levy MJ Kessler E KesslerIcekson G 2003 Expression procollagen Cproteinase enhancer cultured rat heart ﬁbroblasts 17P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 18 evidence coregulation type collagen J Cell Biochem 90 397407 103 de Boer RA De Keulenaer G Bauersachs J Brutsaert Cleland JG Diez J Du XJ Ford P Heinzel FR Lipson KE McDonagh LopezAndres N Lunde IG Lyon AR Pollesello P Prasad SK Tocchetti CG Mayr Sluijter JPG Thum Tschope C Zannad F Zimmermann WH Ruschitzka F Filippatos G Lindsey ML Maack C Heymans 2019 Towards better deﬁnition quantiﬁcation treatment ﬁbrosis heart failure scientiﬁc roadmap Committee Translational Research Heart Failure Association HFA European Society Cardiology Eur J Heart Fail 21 272285 104 Frangogiannis NG 2019 Cardiac ﬁbrosis Cell biological mechanisms molecular pathways therapeutic opportunities Mol Aspects Med 65 7099 105 Gyongyosi Winkler J Ramos QT Firat H McDonald K Gonzalez Thum Diez J Jaisser F Pizard Zannad F 2017 Myocardial ﬁbrosis biomedical research bench bedside Eur J Heart Fail19 177191 106 Cowling RT Kupsky Kahn Daniels LB Greenberg BH 2019 Mechanisms cardiac collagen deposition experimental models human disease Transl Res 209 138155 107 Ghazi L Drawz P 2017 Advances understanding reninangiotensinaldosterone system RAAS blood pressure control recent pivotal trials RAAS blockade heart failure diabetic nephropathy F1000Res 6 108 Freimann KesslerIcekson G Shahar Radom Aizik Yitzhaky Eldar Scheinowitz 2009 Exercise training alters molecular response myocardial infarction Med Sci Sports Exerc 41 757 765 109 Reichert K Pereira Carmo HR Galluce Torina ADiogenes de Carvalho Carvalho Sposito de Souza Vilarinho KA da Mota SilveiraFilho L Martins de Oliveira PPPP Petrucci 2016 Atorvastatin improves ventricular remodeling myocardial infarction interfering collagen metabolism PLoS ONE 11e0166845 110 Hermida N Markl Hamelet J Van Assche Vanderper Herijgers P van Bilsen Hilﬁker Kleiner Noppe G Beauloye C Horman Balligand JL 2013 HMGCoA reductase inhibition reverses myocardial ﬁbrosis diastolic dysfunction AMPactivated protein kinase activation mouse model metabolic syndrome Cardiovasc Res 99 4454 111 Ayyadevara Mercanti F Wang X Mackintosh G Tackett AJ Prayaga SV Romeo F Shmookler Reis RJ Mehta JL 2016 Age hypertension associated protein aggregates mouse heart similar proteomic proﬁles Hypertension 67 10061013 112 Fan Takawale Basu R Patel V Lee J Kandalam V Wang X Oudit GY Kassiri Z 2014 Differential role TIMP2 TIMP3 cardiac hypertrophy ﬁbrosis diastolic dysfunction Cardiovasc Res 103 268280 113 Lagoutte P Oudot Dussoyer Goncalves V Guillemin Bouchot Vandroux Bellaye PSMoali VadonLe Goff 2021 Procollagen C Proteinase Enhancer 1 PCPE1 marker myocardial ﬁbrosis impaired cardiac function murine model pressure overload BioRxiv org10110120210305434071 114 Beaumont J Lopez B Hermida N Schroen B San Jose G Heymans Valencia F GomezDoblas JJ De Teresa E Diez J Gonzalez 2014 microRNA 122 downregulation may play role severe myocardial ﬁbrosis human aortic stenosis TGFbeta1 regulation Clin Sci 126 497506 115 Kritzer MD Li J Passariello CL Gayanilo Thakur H Dayan J DodgeKafka K Kapiloff MS 2014 scaffold protein muscle Akinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required development heart failure Circ Heart Fail 7 663672 116 Chemaly ER Kang Zhang McCollum L Chen J Benard L Purushothaman KR Hajjar RJ Lebeche 2013 Differential patterns replacement reactive ﬁbrosis pressure volume overload related propensity ischaemia involve resistin J Physiol 591 5337 5355 117 Amann K Ridinger H Rutenberg C Ritz E Mall G Maercker C 2003 Gene expression proﬁling global cDNA arrays gives hints concerning potential signal transduction pathways involved cardiac ﬁbrosis renal failure Comp Funct Genomics 4 571583 118 van der Pol Gil Tromp J Sillje HHW van Veldhuisen DJ Voors AA Hoendermis ES Grote Beverborg N Schouten EM de Boer RA Bischoff R van der Meer P 2018 OPLAH ablation leads accumulation 5oxoproline oxidative stress ﬁbrosis elevated ﬁllings pressures murine model heart failure preserved ejection fraction Cardiovasc Res 114 18711882 119 BarallobreBarreiro J Didangelos Schoendube F Drozdov Yin X FernandezCaggiano Willeit P Puntmann VO AldamaLopez G Shah Domenech N Mayr 2012 Proteomics analysis cardiac extracellular matrix remodeling porcine model ischemiareperfusion injury Circulation 125 789802 120 Friedman SL 2008 Mechanisms hepatic ﬁbrogenesis Gastroenterology 134 16551669 121 Tsuchida Friedman SL 2017 Mechanisms hepatic stellate cell activation Nat Rev Gastroenterol Hepatol 14 397411 122 Xiong X Kuang H Ansari Liu Gong J Wang Zhao XY Ji Li C Guo L Zhou L Chen Z LeonMimila P Chung MT Kurabayashi K Opp J CamposPerez F VillamilRamirez H Canizales Quinteros Lyons R Lumeng CN Zhou B Qi L HuertasVazquez Lusis AJ Xu XZS Li Yu Li JZ Lin JD 2019 Landscape intercellular crosstalk healthy NASH liver revealed singlecell secretome gene analysis Mol Cell75644660 e645 123 Hou C Feng W Wei Wang Xu X Wei J Z Du Guo J Kong F Tang R Zheng K 2018 Bioinformatics analysis key differentially expressed genes nonalcoholic fatty liver disease mice models Gene Expr 19 2535 18P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 19 124 Tugues MoralesRuiz FernandezVaro G Ros J Arteta MunozLuque J Arroyo V Rodes J Jimenez W 2005 Microarray analysis endothelial differentially expressed genes liver cirrhotic rats Gastroenterology 129 16861695 125 Hassoun E Safrin Ziv H PriChen Kessler E 2016 Procollagen CProteinase Enhancer 1 PCPE1 plasma marker muscle liver ﬁbrosis mice PLoS ONE 11e0159606 126 Ippolito DL AbdulHameed MD Tawa GJ Baer CE Permenter MG McDyre BC Dennis Boyle MH Hobbs CA Streicker Snowden BS Lewis JA Wallqvist Stallings JD 2016 Gene expression patterns associated histopathology toxic liver ﬁbrosis Toxicol Sci 149 6788 127 Luangmonkong Suriguga Bigaeva E Boersema Oosterhuis de Jong KP Schuppan Mutsaers HAM Olinga P 2017 Evaluating antiﬁbrotic potency galunisertib human ex vivo model liver ﬁbrosis Br J Pharmacol 174 31073117 128 SchusterGaul Geisler LJ McGeough MD Johnson CD Zagorska Li L Wree Barry V Mikaelian Jih LJ Papouchado BG Budas G Hoffman HM Feldstein AE 2020 ASK1 inhibition reduces cell death hepatic ﬁbrosis Nlrp3 mutant liver injury model JCI Insight 5e123294 129 Hassoun E Safrin Wineman E Weiss P Kessler E 2017 Data comparing plasma levels procollagen Cproteinase enhancer 1 PCPE1 healthy individuals liver ﬁbrosis patients Data Brief 14 777781 130 Gokce Ozenirler Atak Yucel Oruklu N Yilmaz Esendagli G Karahan 2018 Evaluation serum procollagen Cproteinase enhancer 1 level ﬁbrosis marker patients chronic hepatitis B Eur J Gastroenterol Hepatol 30 918924 131 Ozkan G Guzel Atar RV Fidan C Kara SP Ulusoy 2019 Elevated serum levels procollagen Cproteinase enhancer1 patients chronic kidney disease associated declining glomerular ﬁltration rate Nephrology Carlton 24 938942 132 Lenaerts Barry 3rd CE Dartois V 2015 Heterogeneity tuberculosis pathology microenvironments therapeutic responses Immunol Rev 264 288307 133 Polak SB Van Gool IC Cohen von der Thu sen JH Van Paassen J 2020 systematic review pathological ﬁndings COVID19 pathophysiological timeline possible mechanisms disease progression Mod Pathol 33 21282138 134 Lynch 3rd JP Huynh RH Fishbein MC Saggar R Belperio JA Weigt SS 2016 Idiopathic pulmonary ﬁbrosis epidemiology clinical features prognosis management Semin Respir Crit Care Med 37 331 357 135 Ryu JH Moua Daniels CE Hartman TE Yi E Utz JP Limper AH 2014 Idiopathic pulmonary ﬁbrosis evolving concepts Mayo Clin Proc 89 1130 1142 136 Schiller HB Fernandez IE Burgstaller G Schaab C Scheltema RA Schwarzmayr Strom TM Eickelberg Mann 2015 Time andcompartmentresolved proteome proﬁling extracellular niche lung injury repair Mol Syst Biol11 819 137 Zhou Horowitz JC Naba Ambalavanan N Atabai K Balestrini J Bitterman PB Corley RADing BS Engler AJ Hansen KC Hagood JS Kheradmand F Lin QS Neptune E Niklason L Ortiz LA Parks WC Tschumperlin DJ White ES Chapman HA Thannickal VJ 2018 Extracellular matrix lung development homeostasis disease Matrix Biol 73 77104 138 EmblomCallahan MC Chhina MK Shlobin OA Ahmad Reese ES Iyer EP Cox DN Brenner R Burton NA Grant GM Nathan SD 2010 Genomic phenotype noncultured pulmonary ﬁbroblasts idiopathic pulmonary ﬁbrosis Genomics 96 134145 139 Yang IV Coldren CD Leach SM Seibold Murphy E Lin J Rosen R Neidermyer AJ McKean DF Groshong SD Cool C Cosgrove G P Lynch DA Brown KK Schwarz MI Fingerlin E Schwartz DA 2013 Expression cilium associated genes deﬁnes novel molecular subtypes idiopathic pulmonary ﬁbrosis Thorax 68 11141121 140 Duerr J Leitz DHW Szczygiel Dvornikov Fraumann SG Kreutz C Zadora PK Seyhan Agircan Konietzke P Engelmann TA Hegermann J Mulugeta Kawabe H Knudsen L Ochs Rotin Muley Kreuter Herth FJF Wielputz MO Beers MF Klingmuller U Mall 2020 Conditional deletion Nedd42 lung epithelial cells causes progressive pulmonary ﬁbrosis adult mice Nat Commun 11 2012 141 LopezNovoa JM MartinezSalgado C Rodriguez Pena AB LopezHernandez FJ 2010 Common pathophysiological mechanisms chronic kidney disease therapeutic perspectives Pharmacol Ther 128 6181 142 Ledo N Ko YA Park Kang HM Han SY Choi P Susztak K 2015 Functional genomic annotation genetic risk loci highlights inﬂammation epithelial biology networks CKD J Soc Nephrol 26 692714 143 Achari Chin JW Heard BJ Rattner JB Shrive NG Frank CB Hart DA 2011 Molecular events surrounding collagen ﬁbril assembly early healing rabbit medial collateral ligamentfailure recapitulate normal ligament development Connect Tissue Res 52 301312 144 Klingler W JurkatRott K LehmannHorn F Schleip R 2012 role ﬁbrosis Duchenne muscular dystrophy Acta Myol 31 184195 145 Li AH Liu PP Villarreal FJ Garcia RA 2014 Dynamic changes myocardial matrix relevance disease translational perspectives Circ Res 114 916 927 146 Raz V Sterrenburg E Routledge Venema van der Sluijs BM Trollet C Dickson G van Engelen B G van der Maarel SM Antoniou MN 2013 Nuclear entrapment extracellular depletion PCOLCE associated muscle degeneration oculopharyngeal muscular dystrophy BMC Neurol 13 70 19P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 20 147 Fini Stramer BM 2005 cornea heals corneaspeciﬁc repair mechanisms affecting surgical outcomes Cornea 24 S2S11 148 Sidgwick GP Bayat 2012 Extracellular matrix molecules implicated hypertrophic keloid scarring J Eur Acad Dermatol Venereol 26 141152 149 Wolfram Tzankov Pulzl P PizaKatzer H 2009 Hypertrophic scars keloidsa review pathophysiology risk factors therapeutic management Dermatol Surg 35 171181 150 Lichtman MK OteroVinas Falanga V 2016 Transforming growth factor beta TGFbeta isoforms wound healing ﬁbrosis Wound Repair Regen 24 215222 151 Kiritsi Nystrom 2018 role TGFbeta wound healing pathologies Mech Ageing Dev 172 51 58 152 Lee SolowCordero DE Kessler E Takahara K Greenspan DS 1997 Transforming growth factor beta regulation bone morphogenetic protein1 procollagen Cproteinase related proteins ﬁbrogenic cells keratinocytes J Biol Chem 272 1905919066 153 L Gan C Huang Wang Luo G Wu J 2014 Comparative proteomic analysis extracellular matrix proteins secreted hypertrophic scar normal skin ﬁbroblasts Burns Trauma 2 7683 154 Naitoh Kubota H Ikeda Tanaka Shirane H Suzuki Nagata K 2005 Gene expression human keloids altered dermal chondrocytic osteogenic lineage Genes Cells 10 10811091 155 Wong VW F Januszyk Gurtner GC Kuang AA 2014 Transcriptional proﬁling rapamycintreated ﬁbroblasts hypertrophic keloid scars Ann Plast Surg 72 711719 156 Grgurevic L Macek B Durdevic Vukicevic 2007 Detection bone cartilagerelated proteins plasma patients bone fracture using liquidchromatographymass spectrometry Int Orthop 31 743751 157 Finehout EJ Franck Z Lee KH 2004 Towards twodimensional electrophoresis mapping cerebrospinal ﬂuid proteome single individual Electrophoresis 25 25642575 158 Yuan X Desiderio DM 2002 Protein identiﬁcation Teﬂon matrixassisted laser desorptionionization sample support J Mass Spectrom 37 512524 159 Guldbrandsen Vethe H Farag Oveland E Garberg H Berle Myhr KM Opsahl JA Barsnes H Berven FS 2014 Indepth characterization cerebrospinal ﬂuid CSF proteome displayed CSF proteome resource CSFPR Mol Cell Proteomics 13 31523163 160 Xiao F Chen Lu Xiao Z Guan LF Yuan J Wang L Xi ZQ Wang XF 2009 Proteomic analysis cerebrospinal ﬂuid patients idiopathic temporal lobe epilepsy Brain Res 1255 180189 161 Kehlet SN Willumsen N Armbrecht G Dietzel R Brix Henriksen K Karsdal 2018 Age related collagen turnover interstitial matrix basement membrane Implications age sex dependent remodeling extracellular matrix PLoS ONE 13e0194458162 Yamaga Taga Minaguchi H 1997 Changes urinary excretions Ctelopeptide crosslinked N telopeptide type collagen pregnancy puerperium Endocr J 44 733738 163 Szulc P 2018 Bone turnover Biology assessment tools Best Pract Res Clin Endocrinol Metab 32 725738 164 Elhai Avouac J Allanore 2020 Circulating lung biomarkers idiopathic lung ﬁbrosis interstitial lung diseases associated connective tissue diseases stand Semin Arthritis Rheum 50 480491 165 Gonzalez Lopez B Ravassa Beaumont J Arias Hermida N Zudaire Diez J 2009 Biochemical markers myocardial remodelling hypertensive heart disease Cardiovasc Res 81 509518 166 Lurie Webb CytterKuint R Shteingart Lederkremer GZ 2015 Noninvasive diagnosis liver ﬁbrosis cirrhosis World J Gastroenterol 21 1156711583 167 Motiwala SR Gaggin HK 2016 Biomarkers predict reverse remodeling myocardial recovery heart failure Curr Heart Fail Rep 13 207218 168 Muir Massoudi Nguyen N Keene DR Lee SJ Birk DE Davidson JM Marinkovich MP Greenspan DS 2016 BMP1like proteinases essential structure wound healing skin Matrix Biol 56 114131 169 Muir Ren Butz DH Davis NA Blank RD Birk DE Lee SJ Rowe Feng JQ Greenspan DS 2014 Induced ablation Bmp1 Tll1 produces osteogenesis imperfecta mice Hum Mol Genet 23 30853101 170 Wang J Massoudi Ren Muir Harris SE Greenspan DS Feng JQ 2017 BMP1 TLL1 required maintaining periodontal homeostasis J Dent Res 96 578585 171 Hinz B 2015 extracellular matrix transforming growth factorbeta1 Tale strained relationship Matrix Biol 47 5465 172 Tschumperlin DJ Lagares 2020 Mechano therapeutics targeting mechanical signaling ﬁbrosis tumor stroma Pharmacol Ther 212107575 173 Newman AC Nakatsu MN Chou W Gershon PD Hughes CC 2011 requirement ﬁbroblasts angiogenesis ﬁbroblastderived matrix proteins essential endothelial cell lumen formation Mol Biol Cell22 37913800 174 Kanaki Morisaki N Bujo H Takahashi K Ishii Saito 2000 regulatory expression procollagen COOHterminal proteinase enhancer proliferation vascular smooth muscle cells Biochem Biophys Res Commun 270 10491054 175 Masuda Igarashi H Kano Yoshikura H 1998 Effects procollagen Cproteinase enhancer protein growth cultured rat ﬁbroblasts revealed excisable retroviral vector Cell Growth Differ 9 381391 176 Matsui Yanase Tomiya Ikeda H Fujiwara K Ogata 2002 Stabilization RNA strands protein synthesis type procollagen Cproteinase enhancer protein potential RNAbinding protein hepatic stellate cells Biochem Biophys Res Commun 290 898902 20P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062 Page 21 177 Wu CH Donovan CB Wu GY 1986 Evidence pretranslational regulation collagen synthesis procollagen propeptides J Biol Chem 261 10482 10484 178 Pettersen EF Goddard TD Huang CC Meng EC Couch GS Croll TI Morris JH Ferrin TE 2021 UCSF ChimeraX Structure visualization researchers educators developers Protein Sci 30 7082 21P Lagoutte E Bettler VadonLe Goff et al Materials Biology 11 2021 100062